Previous allogeneic bone marrow transplant
Patients with previous allogeneic bone marrow transplant
Has had a prior stem cell or bone marrow transplant.
Has received an allogeneic bone marrow or allogeneic stem cell transplant.
ELIGIBILITY CRITERIA FOR BONE MARROW TRANSPLANT
EXCLUSION CRITERIA FOR BONE MARROW TRANSPLANT
History of an allogeneic bone marrow transplant.
Prior allogeneic bone marrow transplant.
Participants who have received a previous allogeneic bone marrow transplant
Suitable for imminent bone marrow transplant, or within  weeks of one.
Bone marrow transplant: patient must be:\r\n* >=  months since allogeneic bone marrow transplant prior to registration\r\n* >=  months since autologous bone marrow/stem cell prior to registration
Autologous or allogeneic stem cell or bone marrow transplant within  months prior to cycle  day 
Participants who are within  months of an allogeneic bone marrow transplant
INCLUSION CRITERIA FOR STRATUM C: Patient must be:\r\n* >=  weeks since autologous bone marrow/stem cell transplant prior to enrollment\r\n* >=  years since allogeneic bone marrow transplant prior to enrollment with no evidence of active graft versus (vs.) host disease
Previous bone marrow or stem cell transplant
Clinically significant pulmonary dysfunction, active infection, prior allogeneic bone marrow transplant, active autoimmune disease
Prior allogeneic bone marrow transplant within  months of screening date
We will exclude patients who are eligible for an allogeneic bone marrow transplant at the time of study enrollment; if an enrolled patient subsequently becomes eligible for transplant, they will not be prevented from proceeding to the appropriate clinical treatment indicated
Prior allogeneic bone marrow- or stem cell-transplant
FOR ALL PHASES (Ib AND II): History of having received an allogeneic bone marrow or organ transplant
Previous allogeneic bone marrow transplant
Prior allogeneic bone marrow transplant
Prior bone marrow or stem cell transplant
Post-transplant bone marrow blast count ? % confirmed by standard of care bone marrow biopsy performed post-transplant (at least  days post-transplant).
Have undergone a prior allogeneic bone marrow transplant (BMT)
Prior stem cell or bone marrow transplant
Prior allogeneic bone marrow/peripheral blood stem cell transplant
History of organ allograft (allogeneic bone marrow or stem cell transplant) within  months prior to first dose of study drug
Prior bone marrow or stem cell transplant.
Subject has undergone a bone marrow transplant
Undergone an organ transplant(s) including allogeneic stem cell or bone marrow transplants
Previous bone marrow or stem cell transplant
Patients with secondary AML, and patients with a prior autologous and allogeneic bone marrow transplant are eligible
Prior allogeneic bone marrow or stem cell transplant
Prior allogeneic bone marrow or stem cell transplant
Pregnancy at the time of bone marrow transplant (BMT)
History of bone marrow transplant;
Receipt of an allogeneic bone marrow or allogeneic stem cell transplant
Patients who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant less than  months prior to initiation of study
Prior bone marrow or stem cell transplant
Has a transplanted organ or has undergone allogeneic bone marrow transplant
Prior autologous or allogeneic bone marrow or stem cell transplant
Prior allogeneic bone marrow transplant
Patients with an organ transplant, including those that have received an allogeneic bone marrow transplant.
History of having received an allogeneic bone marrow or organ transplant
Participant is a candidate for a bone marrow or stem cell transplant within  weeks after study enrollment.
Relapsed and or refractory multiple myeloma after at least one prior line of therapy; there is no upper limit of prior lines of therapy; patients who are ineligible for stem cell transplantation are allowed; patients should have received at least one prior novel agent (immunomodulatory agents or proteasome inhibitors); patients eligible for bone marrow transplant must have undergone bone marrow transplant (BMT) prior to enrollment
Previous allogeneic bone marrow transplant.
Prior autologous or allogeneic bone marrow/peripheral blood stem cell transplant
History of any organ or bone marrow transplant
Patients with a history of bone marrow transplant within the previous two years
The patient had a previous bone marrow or stem cell transplant
Patients with a history of bone marrow transplant within the previous two years
History of allogeneic bone marrow/stem cell transplant
Autologous or allogeneic bone marrow transplant as second-line therapy.
Not eligible for stem cell/bone marrow transplant or have refused stem cell/bone marrow transplant or have relapsed after autologous or allogeneic stem cell/bone marrow transplant
Has had a prior stem cell or bone marrow transplant
Prior bone marrow transplant
Prior bone marrow or stem cell transplant;
Autologous or allogeneic stem cell or bone marrow transplant within  months prior to first dose of study drug.
Has received an allogeneic bone marrow or allogeneic stem cell transplant.
Recent bone marrow transplant
Autologous or allogeneic stem cell or bone marrow transplant within  months prior to first dose of study treatment.
Eligible for allogeneic bone marrow transplant.
No more than  prior lines of systemic anti-cancer therapy and no prior bone marrow transplant or stem cell transplant within  months of dosing, and no prior allogeneic transplant.
Patients with a history of bone marrow transplant within the previous two years
Patients eligible for bone marrow transplant, regardless of age
Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant
All patients must be enrolled within  hours of admission except patients in the bone marrow transplant arm who may be enrolled at the beginning or during their bone marrow transplant
Patients receiving myeloablative chemotherapy in preparation for allogeneic or autologous bone marrow or stem cell transplant
Previous bone marrow transplant
Admission to the University of North Carolina (UNC) Hospital Bone Marrow Transplant Unit for allogeneic stem cell transplant
History of bone marrow transplant
No current or history of a hematologic malignancy is allowed, including subjects who have undergone a bone marrow transplant.
Recipient of a stem cell or bone marrow transplant.
